Special Issue "Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes"

A special issue of Biologics (ISSN 2673-8449). This special issue belongs to the section "Biologics in Respiratory Diseases".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 3391

Special Issue Editors

Institute for Health and Sport, Victoria University, Melbourne, VIC 3011, Australia
Interests: cancer; autoimmunity; mental health; vaccines; exercise; infectious diseases; drugs; healthy aging; bioactives
Special Issues, Collections and Topics in MDPI journals
Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India
Interests: immunology; inflammation; vaccine formulations; vaccine validations; biologics; immunotherapeutics; antigen delivery; infectious diseases
Special Issues, Collections and Topics in MDPI journals
L M College of Pharmacy, Ahmedabad, Gujarat, India
Interests: small molecule designing using CADD techniques; green chemistry; microwave synthesis; alternate synthetic routes for existing drugs

Special Issue Information

Dear Colleagues,

Since the beginning of the pandemic, new “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” variants have emerged that can influence the airborne transmission, virulence, and immune evasion of affected individuals. The neutralizing antibodies produced as a result of vaccination or post-recovery of COVID-19 are not providing sufficient immune protection against emerging SARS-CoV-2 variants. SARS-CoV-2 variant-specific vaccines are required for better protection. A range of treatment options has become available, specifically for the aged, those with underlying health conditions, and the immunocompromised.

This Special Issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the impact of the aged population and immunocompromised patients on SARS-CoV-2 variants, vaccine efficacy, and treatment outcomes.

We cordially invite you to contribute to this Special Issue to advance our knowledge of SARS-CoV-2 and determine the means to overcome the pandemic.

Prof. Dr. Vasso Apostolopoulos
Dr. Vivek P. Chavda
Dr. Mahesh T. Chhabria
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biologics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • COVID-19 and aged population
  • immunological studies
  • immune memory in aged population and immunocompromised patients
  • tracking the viral antigenic shift associated with the different viral variants
  • T and B-cells immune responses induction and durability
  • viral macromolecules circulation, prevalence, and shedding are associated with pathogenesis and/or post-COVID-19 syndromes
  • novel molecule design strategies
  • vaccines, drugs, treatments
  • strategies for further clinical trials

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:


Jump to: Review

Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes
Biologics 2022, 2(3), 165-170; https://doi.org/10.3390/biologics2030013 - 22 Jul 2022
Cited by 1 | Viewed by 1743
Patients with an immunocompromised state are at risk of developing a long-term infection from the coronavirus 2 that causes severe acute respiratory syndrome (SARS-CoV-2) [...] Full article
Show Figures

Figure 1


Jump to: Editorial

A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities
Biologics 2023, 3(2), 138-157; https://doi.org/10.3390/biologics3020008 - 09 Jun 2023
Viewed by 1031
The SARS-CoV-2 virus has caused a catastrophic impact on the world for the past 3 years. The virus has now returned with the emergence of the Omicron (B.1.1.529) variant. Within two months of its first emergence in South Africa, Omicron became the most [...] Read more.
The SARS-CoV-2 virus has caused a catastrophic impact on the world for the past 3 years. The virus has now returned with the emergence of the Omicron (B.1.1.529) variant. Within two months of its first emergence in South Africa, Omicron became the most dominating SARS-CoV-2 variant around the world, being the cause of the majority of new infections at present. Omicron has presented with the greatest transmission rate of all the previous variants despite the presence of mass vaccinations and acquired immunity. Several monoclonal antibodies and mRNA vaccines have failed to produce desired effects owing to a large number of mutations present in the Omicron variant. The introduction of the booster dose of the present mRNA vaccines has proven to be a great addition to the therapeutic armamentarium against the Omicron variant. Immunocompromised patients including the elderly, cancer patients, organ transplant recipients, and those with multiple comorbidities have been at a greater risk of developing severe diseases since the pre-Omicron era. The emergence of Omicron again raised a threat against this population. The protection from severe disease and mortality rates through the utilization of multiple immunizations and monoclonal antibodies has been controversial in this subgroup of patients. Thus, designing large-scale studies to evaluate the effectiveness of monoclonal antibodies and vaccines in these patients can provide evidence-based recommendations to improve survival in this population. This article attempts to discuss the different subvariants of Omicron, differences in the mutational aspects along with the particular focus on the consequences of the Omicron infection in the elderly population with diverse comorbidities. Full article
Show Figures

Figure 1

Back to TopTop